Trial Profile
A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 20 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2014 to 1 May 2014.